ES2097878T3 - Fijacion de p53 sobre el adn mediante una secuencia especifica. - Google Patents

Fijacion de p53 sobre el adn mediante una secuencia especifica.

Info

Publication number
ES2097878T3
ES2097878T3 ES92305333T ES92305333T ES2097878T3 ES 2097878 T3 ES2097878 T3 ES 2097878T3 ES 92305333 T ES92305333 T ES 92305333T ES 92305333 T ES92305333 T ES 92305333T ES 2097878 T3 ES2097878 T3 ES 2097878T3
Authority
ES
Spain
Prior art keywords
dna
sequences
fixation
wild
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92305333T
Other languages
English (en)
Inventor
Bert Vogelstein
Kenneth W Kinzler
Michael I Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmagenics Inc
Johns Hopkins University
Original Assignee
Pharmagenics Inc
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27109289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097878(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmagenics Inc, Johns Hopkins University filed Critical Pharmagenics Inc
Application granted granted Critical
Publication of ES2097878T3 publication Critical patent/ES2097878T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LAS SECUENCIAS ESPECIFICAS EN EL GENOMA HUMANO SON LOS LUGARES DE FUERTE UNION DE LA PROTEINA DE TIPO SALVAJE P53, PERO NO DE LAS FORMAS MUTANTES DE LA PROTEINA. ESTAS SECUENCIAS SE USAN EN PROCEDIMIENTOS DE DIAGNOSTICO PARA DETECTAR CELULAS EN LAS CUALES LA CANTIDAD DE P53 DE TIPO SALVAJE HA SIDO DISMINUIDA. LAS SECUENCIAS PUEDEN USARSE TAMBIEN PARA FILTRAR AGENTES QUE CORRIGEN LA PERDIDA DEL P53 DE TIPO SALVAJE EN EL DNA DE LAS CELULAS DEL CANCER.
ES92305333T 1991-06-14 1992-06-10 Fijacion de p53 sobre el adn mediante una secuencia especifica. Expired - Lifetime ES2097878T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71518291A 1991-06-14 1991-06-14
US07/860,758 US5362623A (en) 1991-06-14 1992-03-31 Sequence specific DNA binding by p53

Publications (1)

Publication Number Publication Date
ES2097878T3 true ES2097878T3 (es) 1997-04-16

Family

ID=27109289

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305333T Expired - Lifetime ES2097878T3 (es) 1991-06-14 1992-06-10 Fijacion de p53 sobre el adn mediante una secuencia especifica.

Country Status (10)

Country Link
US (4) US5362623A (es)
EP (1) EP0518650B1 (es)
JP (1) JPH0678798A (es)
AT (1) ATE147512T1 (es)
AU (1) AU666479B2 (es)
CA (1) CA2070979C (es)
DE (1) DE69216478T2 (es)
DK (1) DK0518650T3 (es)
ES (1) ES2097878T3 (es)
GR (1) GR3022473T3 (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) * 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
DE69333289T2 (de) * 1992-04-01 2004-08-26 The Johns Hopkins University School Of Medicine Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien
US5670330A (en) * 1992-09-29 1997-09-23 Mcgill University Anti-tumor agent assay using PKR
CA2144768A1 (en) * 1992-10-01 1994-04-14 Stephen H. Friend Functional assay for tumor supressor genes
DE69433915T2 (de) * 1993-05-14 2005-07-21 Cancer Institute MDC-Proteine und dafür kodierende DNS
US5659024A (en) * 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
WO1996005308A1 (en) * 1994-08-12 1996-02-22 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
US5721340A (en) * 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
AU6643596A (en) * 1995-08-11 1997-03-12 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Isolation of amplified genes via cdna subtractive hybridization
EP0859956B1 (en) 1995-09-18 2003-07-02 Cancer Research Technology Limited ASSAY FOR IDENTIFYING INHIBITORS OF THE INTERACTION BETWEEN PROTEINS p53 AND dm2
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5847083A (en) * 1996-08-21 1998-12-08 The Wistar Institute Of Anatomy And Biology Modified p53 constructs which enhance DNA binding
AU7242996A (en) * 1995-09-22 1997-04-09 Wistar Institute Of Anatomy And Biology, The Modified p53 constructs and uses therefor
PL186018B1 (pl) * 1995-11-30 2003-09-30 Regents Board Of Sposoby i kompozycje do diagnozowania i leczenia nowotworu
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6242212B1 (en) * 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
JPH09252783A (ja) * 1996-03-26 1997-09-30 Nippon Suisan Kaisha Ltd 腸炎ビブリオ検出のためのヌクレオチドおよびそれを用いた検出法
US5861249A (en) * 1996-04-23 1999-01-19 Cold Spring Harbor Laboratory Assays and reagents for identifying modulators of cdc25-mediated mitotic activation
US5830751A (en) * 1996-05-01 1998-11-03 The Johns Hopkins University Genetic assays and strains using human TP53
US5876711A (en) * 1996-05-31 1999-03-02 Onyx Pharmaceuticals, Inc. Methods and compositions for determining the tumor suppressor status of cells
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5744310A (en) * 1996-07-29 1998-04-28 The Burnham Institute Bax promoter sequence and screening assays for indentifying agents that regulate bax gene expression
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
AU8284198A (en) 1997-07-02 1999-01-25 Board Of Regents, The University Of Texas System P53 as a regulator of cell differentiation
CA2214461A1 (en) * 1997-09-02 1999-03-02 Mcgill University Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6388062B1 (en) 1998-05-08 2002-05-14 The Wistar Institute Of Anatomy And Biology Modified p53 tetramerization domains having hydrophobic amino acid substitutions
AU1115300A (en) 1998-10-13 2000-05-01 Advanced Research And Technology Institute, Inc. Assays for identifying functional alterations in the p53 tumor suppressor
DE19847779C1 (de) 1998-10-16 2000-02-03 Deutsches Krebsforsch p53-Bindungsregionen
US6911307B1 (en) * 1998-12-08 2005-06-28 Proteus S.A. Method of detection in vitro of a target substance in a sample comprising the labelling of said substance with a reporter gene and with the sequences necessary for the expression of said reporter gene in vitro
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
ES2269102T3 (es) 1999-02-25 2007-04-01 Exact Sciences Corporation Procedimientos para conservar la integridad del adn.
AU767983B2 (en) 1999-04-09 2003-11-27 Esoterix Genetic Laboratories, Llc Methods for detecting nucleic acids indicative of cancer
US6297013B1 (en) 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
CA2394921A1 (en) * 1999-12-07 2001-06-14 Anthony P. Shuber Supracolonic aerodigestive neoplasm detection
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
US6831155B2 (en) * 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US6989239B2 (en) * 2001-06-20 2006-01-24 R.E.D. Laboratories, N.V./S.A. Methods for diagnosis and treatment of chronic immune diseases
WO2003058201A2 (en) * 2001-12-31 2003-07-17 Quark Biotech, Inc. Methods for identifying marker genes for cancer
WO2003071252A2 (en) 2002-02-15 2003-08-28 Exact Sciences Corporation Methods for analysis of molecular events
JP4051327B2 (ja) * 2003-09-19 2008-02-20 新科實業有限公司 垂直磁気記録ヘッドおよびその製造方法、ならびに磁気記録装置
US7981607B2 (en) 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
MX2007002169A (es) 2004-08-27 2007-08-14 Cyclacel Ltd Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
WO2007044071A2 (en) 2005-04-21 2007-04-19 Exact Sciences Corporation Analysis of heterogeneous nucleic acid samples
WO2011119934A2 (en) * 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
US8470967B2 (en) * 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
AU2012212127B2 (en) 2011-02-02 2016-06-02 Exact Sciences Corporation Digital sequence analysis of DNA methylation
ES2712798T3 (es) 2013-03-14 2019-05-14 Exact Sciences Dev Co Llc Detección de neoplasias
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10253358B2 (en) 2013-11-04 2019-04-09 Exact Sciences Development Company, Llc Multiple-control calibrators for DNA quantitation
CN104946737B (zh) 2013-12-11 2019-02-22 安可济控股有限公司 用于检测罕见序列变体的组合物和方法
US11286519B2 (en) 2013-12-11 2022-03-29 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
US11859246B2 (en) 2013-12-11 2024-01-02 Accuragen Holdings Limited Methods and compositions for enrichment of amplification products
EP4209600A1 (en) 2013-12-19 2023-07-12 Exact Sciences Corporation Synthetic nucleic acid control molecules
WO2015153283A1 (en) 2014-03-31 2015-10-08 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
EP3274440A4 (en) 2015-03-27 2019-03-06 Exact Sciences Corporation PROOF OF DISEASES OF THE DISHES
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
CN108138235B (zh) 2015-08-31 2022-04-15 梅约医药教育及研究基金会 检测胃肿瘤
KR20180055905A (ko) 2015-10-09 2018-05-25 아큐라젠 홀딩스 리미티드 증폭 산물의 농축을 위한 방법 및 조성물
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CA3020628A1 (en) 2016-04-14 2017-10-19 Mayo Foundation For Medical Education And Research Detecting pancreatic high-grade dysplasia
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
US11427866B2 (en) 2016-05-16 2022-08-30 Accuragen Holdings Limited Method of improved sequencing by strand identification
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
SG11201901296TA (en) 2016-08-15 2019-03-28 Accuragen Holdings Ltd Compositions and methods for detecting rare sequence variants
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN110431241B (zh) 2017-02-28 2024-04-19 梅约医学教育与研究基金会 检测前列腺癌
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
CN107656059B (zh) * 2017-09-26 2019-06-18 中南大学 一种用于p53蛋白的荧光检测剂及其制备方法和应用
AU2018374176A1 (en) 2017-11-30 2020-06-11 Exact Sciences Corporation Detecting breast cancer
US11203782B2 (en) 2018-03-29 2021-12-21 Accuragen Holdings Limited Compositions and methods comprising asymmetric barcoding
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204922A3 (en) * 1985-05-28 1987-09-30 Abbott Laboratories Immunohistochemical assay for detection of a tumor-associated marker (p53)
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US4917999A (en) * 1986-09-02 1990-04-17 Miles Inc. Oligonucleotide probes for detection of α-amylase genes
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
DE69032864T3 (de) * 1989-03-29 2013-01-31 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
NZ233255A (en) * 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
US5068175A (en) * 1989-05-26 1991-11-26 Board Of Regents, The University Of Texas Sysem Method of detecting ras oncogene related malignancies
ES2164045T3 (es) * 1990-06-27 2002-02-16 Univ Princeton Sondas para la deteccion de p53 mutante.
AU650677B2 (en) * 1990-09-24 1994-06-30 General Hospital Corporation, The Screening assays
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5571903A (en) * 1993-07-09 1996-11-05 Lynx Therapeutics, Inc. Auto-ligating oligonucleotide compounds

Also Published As

Publication number Publication date
US20020164595A1 (en) 2002-11-07
US5955263A (en) 1999-09-21
CA2070979C (en) 2006-01-03
AU1820092A (en) 1992-12-17
ATE147512T1 (de) 1997-01-15
JPH0678798A (ja) 1994-03-22
EP0518650A2 (en) 1992-12-16
AU666479B2 (en) 1996-02-15
US5362623A (en) 1994-11-08
US6245515B1 (en) 2001-06-12
GR3022473T3 (en) 1997-05-31
DE69216478T2 (de) 1998-02-19
DK0518650T3 (da) 1997-01-27
DE69216478D1 (de) 1997-02-20
CA2070979A1 (en) 1992-12-15
EP0518650A3 (en) 1993-01-20
EP0518650B1 (en) 1997-01-08
US7087583B2 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
ES2097878T3 (es) Fijacion de p53 sobre el adn mediante una secuencia especifica.
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
EP0809513A4 (en) NUCLEIC ACID OF RECOMBINANT ENCAPSIDE POLIOVIRUS
LU91498I2 (fr) Etanercept et ses dérivés pharmaceutiquement acceptables.
DK0980429T3 (da) Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder
DE68927025D1 (de) HIV-2-Virusvarianten
DE3681536D1 (de) Beutel fuer medizinische zwecke.
DE69417426T2 (de) N2s2-chelatoren des hydrazino-typs
NO895188D0 (no) Polyamid/gummiblanding og fremgangsmaate for dens fremstilling.
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
GR3017770T3 (en) Feline infectious peritonitis virus diagnostic tools.
DE69434384D1 (de) Metalkomplexbildner
DE69230671D1 (de) Impfstoffe gegen actinobacillus pleuropneumonie
EP0110791A3 (en) Peptides containing an immunogenic site of the poliovirus, and dna's containing nucleotide fragments encoding for these peptides
DK164253C (da) Parasol med et aggregat til fastklemning af parasolstangen i et fodroer.
DE69000820D1 (de) Zusammengestelltes material fuer medizinische verwendung.
DE3766564D1 (de) Kohlenstoffelektroden.
NO864986L (no) Rekombinant resintoksin.
DK7187A (da) Holder til armeringsjern til anvendelse i forbindelse med betontilslutninger
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao
KR880019286U (ko) 정력 단련구
ES1006481Y (es) Braga-panal de un solo uso.
ATE99906T1 (de) Zange zum spreizen von wirbelsaeulenkoerpern.
IT8934058V0 (it) Insieme ammortizzato per bicicletta (kit).

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 518650

Country of ref document: ES